Related Experiment Video
Updated: Jul 25, 2026

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
Published on: May 2, 2011
SARS-CoV-2 and Stroke in a New York Healthcare System
Shadi Yaghi1, Koto Ishida1, Jose Torres1
1Department of Neurology (S.Y., K.I., J.T., K.H., T.T., K.L., S.A., M.S., S.K., E.S., A.L., J.F.), NYU Langone Health, New York, NY.
Insights
Patients with COVID-19 and ischemic stroke had more cryptogenic strokes and higher mortality. Further research is needed on anticoagulation for stroke prevention in coronavirus disease 2019 patients.
Area of Science:
- Neurology
- Infectious Diseases
- Cardiology
Background:
- Coronavirus disease 2019 (COVID-19) is associated with coagulopathy and thromboembolic events.
- Ischemic stroke is a potential complication, but data on its characteristics and outcomes in COVID-19 patients are limited.
Purpose of the Study:
- To investigate the clinical characteristics, stroke mechanisms, and outcomes of ischemic stroke in patients with COVID-19.
- To compare these patients with contemporary and historical stroke cohorts without COVID-19.
Main Methods:
- Retrospective cohort study of ischemic stroke patients hospitalized between March and April 2020.
- Comparison of COVID-19 positive stroke patients with contemporary (COVID-19 negative) and historical stroke controls.
Main Results:
- 0.9% of hospitalized COVID-19 patients had ischemic stroke.
- Cryptogenic stroke was more frequent in COVID-19 patients (65.6%).
- COVID-19 stroke patients exhibited higher NIH Stroke Scale scores, elevated D-dimer levels, and increased mortality compared to controls.
Conclusions:
- Ischemic stroke in COVID-19 patients is rare but associated with a higher proportion of cryptogenic strokes and increased mortality.
- Acquired hypercoagulability may contribute to stroke in COVID-19.
- Further studies are required to evaluate the role of therapeutic anticoagulation for stroke prevention in COVID-19.
Background And Purpose:
With the spread of coronavirus disease 2019 (COVID-19) during the current worldwide pandemic, there is mounting evidence that patients affected by the illness may develop clinically significant coagulopathy with thromboembolic complications including ischemic stroke. However, there is limited data on the clinical characteristics, stroke mechanism, and outcomes of patients who have a stroke and COVID-19.
Methods:
We conducted a retrospective cohort study of consecutive patients with ischemic stroke who were hospitalized between March 15, 2020, and April 19, 2020, within a major health system in New York, the current global epicenter of the pandemic. We compared the clinical characteristics of stroke patients with a concurrent diagnosis of COVID-19 to stroke patients without COVID-19 (contemporary controls). In addition, we compared patients to a historical cohort of patients with ischemic stroke discharged from our hospital system between March 15, 2019, and April 15, 2019 (historical controls).
Results:
During the study period in 2020, out of 3556 hospitalized patients with diagnosis of COVID-19 infection, 32 patients (0.9%) had imaging proven ischemic stroke. Cryptogenic stroke was more common in patients with COVID-19 (65.6%) as compared to contemporary controls (30.4%, P=0.003) and historical controls (25.0%, P<0.001). When compared with contemporary controls, COVID-19 positive patients had higher admission National Institutes of Health Stroke Scale score and higher peak D-dimer levels. When compared with historical controls, COVID-19 positive patients were more likely to be younger men with elevated troponin, higher admission National Institutes of Health Stroke Scale score, and higher erythrocyte sedimentation rate. Patients with COVID-19 and stroke had significantly higher mortality than historical and contemporary controls.
Conclusions:
We observed a low rate of imaging-confirmed ischemic stroke in hospitalized patients with COVID-19. Most strokes were cryptogenic, possibly related to an acquired hypercoagulability, and mortality was increased. Studies are needed to determine the utility of therapeutic anticoagulation for stroke and other thrombotic event prevention in patients with COVID-19.
Related Concept Videos
Acute Coronary Syndrome IV: Interprofessional Care
Atherosclerosis IV: Nursing Management
Stroke: Introduction and Types
Ischemic Stroke l: Introduction
Hemorrhagic Stroke l: Introduction
Hemorrhagic Stroke ll: Pathophysiology

